Research in the UAE

Alopecia Areata Post-Alemtuzumab in MS

Published on Fri, 1 Dec 2023

A Case of Alopecia Areata Following Alemtuzumab in a Patient with Multiple Sclerosis

This case report details a 33-year-old male with relapsing-remitting multiple sclerosis who developed alopecia areata in his beard two years after his second alemtuzumab cycle. While alemtuzumab is known for triggering secondary autoimmune conditions, alopecia areata remains a rare and delayed side effect. Infectious and autoimmune causes were ruled out, and the condition was confirmed by a dermatologist. Treatment with local steroids showed partial improvement. This case adds to the growing evidence of delayed autoimmune manifestations linked to alemtuzumab therapy.

Related research

Learn More
Switching from Fingolimod/Natalizumab to Cladribine Without Rebound
Fri, 1 Dec 2023

Switching from Fingolimod/Natalizumab to Cladribine Without Rebound

Learn More
Learn More
Adherence Challenges for High-Efficacy MS Therapies
Fri, 22 May 2020

Adherence Challenges for High-Efficacy MS Therapies

Learn More
Learn More
Living with MS: A Biopsychosocial Perspective
Tue, 17 Aug 2021

Living with MS: A Biopsychosocial Perspective